Impact of Pseudomonas aeruginosa on resource utilization and costs in patients with exacerbated non-cystic fibrosis bronchiectasis

References

• Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet. 2018;392(10150):880–890. doi: 10.1016/S0140-6736(18)31767-7.
   PubMed Web of Science ®Google Scholar
• Maselli DJ, Amalakuhan B, Keyt H, et al. Suspecting non-cystic fibrosis bronchiectasis: what the busy primary care clinician needs to know. Int J Clin Pract. 2017;71(2):e12924. doi: 10.1111/ijcp.12924.
   PubMed Web of Science ®Google Scholar
• Noone JG, Blanchette C, Zacherle E, et al. Estimates of the prevalence of non-cystic fibrosis bronchiectasis in the US Presented at the American Thoracic Society International Conference, Washington DC, May 21, 2017.
   Google Scholar
• Martinez-Garcia MA, Polverino E, Aksamit T. Bronchiectasis and chronic airway disease: it is not just about asthma and COPD. Chest. 2018;154(4):737–739. doi: 10.1016/j.chest.2018.02.024.
   PubMed Web of Science ®Google Scholar
• Weycker D, Edelsberg J, Oster G, et al. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12(4):205–209. doi: 10.1097/01.cpm.0000171422.98696.
   Google Scholar
• Munteanu O, Chesov D, Rusu D, et al. Mortality related risk factors in patients with non-cystic fibrosis bronchiectasis. Eur Respir J. 2022;60(suppl 66):4014. doi: 10.1183/13993003.congress-2022.4014.
   Google Scholar
• Sin S, Yun SY, Kim JM, et al. Mortality risk and causes of death in patients with non-cystic fibrosis bronchiectasis. Respir Res. 2019;20(1):271. doi: 10.1186/s12931-019-1243-3.
   PubMed Web of Science ®Google Scholar
• Finch S, McDonnell MJ, Abo-Leyah H, et al. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonisation on prognosis in adult bronchiectasis. Ann Am Thorac Soc. 2015;12(11):1602–1611. doi: 10.1513/AnnalsATS.201506-333OC.
   PubMed Web of Science ®Google Scholar
• Wang R, Ding S, Lei C, et al. The contribution of Pseudomonas aeruginosa infection to clinical outcomes in bronchiectasis: a prospective cohort study. Ann Med. 2021;53(1):459–469. doi: 10.1080/07853890.2021.1900594.
   PubMed Web of Science ®Google Scholar
• Imam JS, Duarte AG. Non-CF bronchiectasis: orphan disease no longer. Respir Med. 2020;166:105940. doi: 10.1016/j.rmed.2020.105940.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015;45(5):1446–1462. doi: 10.1183/09031936.00119114.
   PubMed Web of Science ®Google Scholar
• Quittner AL, O’Donnell AE, Salathe MA, et al. Quality of life questionnaire-bronchiectasis: final psychometric analyses and determination of minimal important difference scores. Thorax. 2015;70(1):12–20. doi: 10.1136/thoraxjnl-2014-205918.
   PubMed Web of Science ®Google Scholar
• Lee AL, Hill CJ, McDonald CF, et al. Pulmonary rehabilitation in individuals with non–cystic fibrosis bronchiectasis: a systematic review. Arch Phys Med Rehabil. 2017;98(4):774–782.e1. doi: 10.1016/j.apmr.2016.05.017.
   PubMed Web of Science ®Google Scholar
• Dhand R. The rationale and evidence for use of inhaled antibiotics to control Pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv. 2018;31(3):121–138. doi: 10.1089/jamp.2017.1415.
   PubMed Web of Science ®Google Scholar
• Wilson R, Aksamit T, Aliberti S, et al. Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. Respir Med. 2016;117:179–189. doi: 10.1016/j.rmed.2016.06.007.
   PubMed Web of Science ®Google Scholar
• Laska IF, Crichton ML, Shoemark A, et al. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis. Lancet Respir Med. 2019;7(10):855–869. doi: 10.1016/S2213-2600(19)30185-7.
   PubMed Web of Science ®Google Scholar
• Hill AT, Sullivan AL, Chalmers JD, et al. British thoracic society guideline for bronchiectasis in adults. Thorax. 2019;74(Suppl 1):1–69. doi: 10.1136/thoraxjnl-2018-212463.
   Web of Science ®Google Scholar
• Chalmers JD, Chang AB, Chotirmall SH, et al. Bronchiectasis. Nat Rev Dis Primers. 2018;4(1):45. doi: 10.1038/s41572-018-0042-3.
   PubMed Web of Science ®Google Scholar
• Goeminne PC, Hernandez F, Diel R, et al. The economic burden of bronchiectasis – known and unknown: a systematic review. BMC Pulm Med. 2019;19(1):54. doi: 10.1186/s12890-019-0818-6.
   PubMed Web of Science ®Google Scholar
• Blanchette C, Noone J, Stone G, et al. Healthcare use and costs among patients with non-cystic fibrosis bronchiectasis in the United States. In: am J Respir Crit Care Med. 2016;193:A2939.
   Google Scholar
• Blanchette CM, Noone JM, Stone G, et al. Healthcare cost and utilization before and after diagnosis of Pseudomonas aeruginosa among patients with non-cystic fibrosis bronchiectasis in the U.S. Med Sci (Basel). 2017;5(4):20. doi: 10.3390/medsci5040020.
   PubMedGoogle Scholar
• Quan H, Li B, Couris CM, et al. Updating and validating the charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. doi: 10.1093/aje/kwq433.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8.
   PubMedGoogle Scholar
• Choate R, Aksamit TR, Mannino D, et al. Pseudomonas aeruginosa associated with severity of non-cystic fibrosis bronchiectasis measured by the modified bronchiectasis severity score (BSI) and the FACED: the US bronchiectasis and NTM Research Registry (BRR) study. Respir Med. 2021;177:106285. doi: 10.1016/j.rmed.2020.106285.
   PubMed Web of Science ®Google Scholar